Radiopharmaceutical Logistics and Manufacturing Advances Fuel Growth in Targeted Cancer Therapies

In the first of a three-part interview with BioPharm International®, Andrea Zobel, senior manager of dangerous goods at Cencora World Courier, and Marco Hogenboom, senior director of specialty logistics of Cencora World Courier, discussed how advances in radiopharmaceutical development are creating new opportunities in oncology while introducing complex manufacturing, transportation, and supply chain challenges.

Radiopharmaceutical therapies are emerging as one of the fastest-growing areas of oncology, driven by advances in cancer biology, targeted therapeutics, and isotope manufacturing, according to experts interviewed at the BIO International Convention.

“We know much more today about cancer cells, including which proteins and specific targets are present on those cells and which molecules can bind to them,” said Andrea Zobel. “Now, we can attach a radioactive molecule to these targeted biopharmaceuticals, allowing them to bind directly to cancer cells and deliver highly potent radiation over a very short distance to destroy the tumor cells,” said Zobel.

Zobel explained that decades of progress in understanding cancer biology have created the foundation for radiopharmaceutical development. Researchers can now identify tumor-specific targets and pair them with radioactive isotopes capable of delivering localized radiation directly to cancer cells while minimizing damage to surrounding tissue.

How are logistics challenges affecting radiopharmaceutical commercialization?

While scientific advances are driving a growing pipeline of radiopharmaceutical candidates, commercialization presents unique operational challenges, according to Marco Hogenboom.

Hogenboom noted that interest from pharmaceutical companies has accelerated as radiopharmaceutical programs advance through clinical development. However, transporting radioactive materials requires specialized logistics capabilities and regulatory expertise that vary significantly across regions and countries.

He highlighted differences in transportation requirements across Europe, where regulations may differ not only between countries but also within individual jurisdictions. As a result, pharmaceutical companies and contract research organizations often underestimate the complexity of establishing radiopharmaceutical supply chains.

Despite these hurdles, both speakers expressed optimism about the future of the field. With commercially successful products already reaching patients and additional therapies progressing through development, advances in manufacturing, distribution, and regulatory coordination are expected to help expand patient access to targeted radiopharmaceutical treatments across a broader range of cancer indications.